NGM Biopharmaceuticals, Inc. Common Stock
NGM
NGM was delisted on the 4th of April, 2024.
128 hedge funds and large institutions have $690M invested in NGM Biopharmaceuticals, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 53 increasing their positions, 29 reducing their positions, and 17 closing their positions.
492% more call options, than puts
Call options by funds: $7.99M | Put options by funds: $1.35M
83% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 29
35% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 17
14% more capital invested
Capital invested by funds: $607M → $690M (+$82.6M)
5.92% more ownership
Funds ownership: 59.72% → 65.63% (+5.9%)
4% more funds holding
Funds holding: 123 → 128 (+5)
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$34.3M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$27.2M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
+$12.9M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.51M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$4.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$14.5M |
| 2 |
Millennium Management
New York
|
-$3.19M |
| 3 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$2.73M |
| 4 |
PGH
Partners Group Holding
Baar-Zug,
Switzerland
|
-$2.27M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$1.72M |
NGM Hedge Fund Activity: Q3 2022 in Review
128 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in NGM Biopharmaceuticals, Inc. Common Stock (NGM) for Q3 2022, worth a combined $690M — up 14% from $607M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new NGM positions and 17 closed out — a net gain of 6 holders — while 53 added to existing stakes and 29 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $34.3M. The largest seller was Point72 Asset Management, cutting an estimated $14.5M.
- 128 institutional investors held NGM Biopharmaceuticals, Inc. Common Stock (NGM) as of Q3 2022, up from 123 in Q2 2022.
- Funds reported $690M of NGM Biopharmaceuticals, Inc. Common Stock stock for Q3 2022, up 14% quarter-over-quarter.
- 23 funds opened new NGM Biopharmaceuticals, Inc. Common Stock positions in Q3 2022 and 17 closed out, a net change of +6 holders.
- The largest NGM Biopharmaceuticals, Inc. Common Stock buyer in Q3 2022 was Fidelity Investments, an estimated $34.3M added.
- The largest NGM Biopharmaceuticals, Inc. Common Stock seller in Q3 2022 was Point72 Asset Management, an estimated $14.5M sold.
Based on aggregated 13F filings for Q3 2022.